Chronic pain, stress and sleep issues affect the health and well-being of millions of people – proper solutions to these problems reflect multi-billion dollar markets.
SynBiotic is a biotech platform striving to challenge the status quo and bring innovation to the solution of these global problems. With our buy & build strategy, we cover the whole value chain and transform the healing power of cannabinoids & terpenes into better solutions for complex problems.
People are looking for solutions to their real-life problems. With cannabinoids we are able to address a multi-billion EU-market for sleep, pain and anxiety solutions with cumulative sales of over € 250 billion for OTC and pharmaceuticals in 2020.
people with sleep-related problems, such as disturbed sleep
people with chronic pain and similar issues
people with anxiety
SynBiotic’s organizational structure is built to cover all value drivers – from research over production to distribution
Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.
Most CBX* have not been discovered yet, but studies show that other cannabinoids, beyond THC and CBD, have huge medical potential. In addition, the so called entourage effectis a term used to describe the synergistic effects of combining various chemical compounds found in cannabis. Most commonly, it refers to the interaction between THC/CBD and other cannabinoids or terpenes.
* CBX = all cannabinoids except THC
While CBD from hemp & cannabis plants is still a legal grey area, we focus in parallel on other plants that are rich in cannabinoids, endocannabinoids & terpenes.
Apeiron Investment Group acquires all SynBiotic SE shares of Social Chain AG Munich, September 16, 2021. Apeiron Investment Group has acquired all of Social Chain